A Study of LY4268989 (MORF 057) in Healthy Participants

Part of paid clinical trials in Daytona Beach, Florida.

Sponsor
Eli Lilly and Company
Study ID
NCT07707375
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Healthy

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

Study Details

The purpose of this study is to identify if two different tablets of LY4268989 (MORF 057) work similarly in healthy participants given different meals. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. There will be 18 inpatient stays at the clinical research unit (CRU). The study will last about 9 weeks.

Key Dates

First listed
Jul 16, 2026
Start date
Jul 31, 2026
Status verified
Jul 2026
Primary completion
Oct 31, 2026
Completion
Oct 31, 2026

Study Design

Enrollment
50 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: LY4268989 Treatment A
    Participants will receive LY4268989 single dose T1 orally with high-fat meal
  • Experimental: LY4268989 Treatment B
    Participants will receive LY4268989 single dose T2 orally with high-fat meal
  • Experimental: LY4268989 Treatment C
    Participants will receive LY4268989 single dose T2 orally in a fasted state
  • Experimental: LY4268989 Treatment D
    Participants will receive LY4268989 single dose T3 orally with high-fat meal
  • Experimental: LY4268989 Treatment E
    Participants will receive LY4268989 single dose T3 orally in a fasted state
  • Experimental: LY4268989 Treatment F
    Participants will receive LY4268989 single dose T1 orally in a fasted state

Primary Outcome Measure

Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4268989 [ Time Frame: Day 1 to Day 18 ]

Central Contacts

  • Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
    1-317-615-4559
    [email protected]
  • Physicians interested in becoming principal investigators please contact
    [email protected]

Locations (1)

FacilityCityStateZIPSite coordinators
Fortrea Clinical Research UnitDaytona BeachFlorida32117
386-366-6400
Hugh Coleman (PRINCIPAL_INVESTIGATOR)

Find similar trials in Daytona Beach, FL

By research site
Fortrea Clinical Research Unit· Daytona Beach, FL

Related Studies